Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCA3 and TMPRSS2-ERG score changes during initiation of androgen deprivation therapy with triptorelin in advanced prostate cancer
2009-012786-58Phase 3Completed
- Sponsor
- Ipsen
- Start
- Sep 2009
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of triptorelin in prostate cancer (PCa), sponsored by Ipsen. Started Sep 2009; status: completed.
02
Drugs
triptorelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2009-012786-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012786-58.